ESMO Open

Published by: European Society for Medical Oncology  

People

  1. Abou-Alfa
    Abou-Alfa
  2. Jones
    Jones
  3. Morris
    Morris
  4. Motzer
    Motzer
  5. Park
    Park
  6. Perales
    Perales
  7. Scher
    Scher

Groups

  1. Department of Medicine (7)
  2. Solid Tumor Oncology Division (5)
  3. Center for Hematologic Malignancies (2)
  4. Gastrointestinal Oncology Service (2)
  5. Genitourinary Oncology Service (2)
  6. Hematologic Malignancies, Division of (2)
  7. Adult Leukemia (1)
  8. Bone Marrow Transplant (1)
  9. Exercise Oncology Service (1)
  10. Population Sciences Research Program (1)
Search Within
  1. "2020"
Formats
  1. Journal Article (4)
  2. Review (2)
  3. Miscellaneous (1)
Groups
  1. Department of Medicine (7)
  2. Solid Tumor Oncology Division (5)
  3. Center for Hematologic Malignancies (2)
  4. Gastrointestinal Oncology Service (2)
  5. Genitourinary Oncology Service (2)
  6. Hematologic Malignancies, Division of (2)

More Groups

People
  1. Ghassan Abou-Alfa (2)
  2. Ana Alarcon Tomas (1)
  3. Howard Scher (1)
  4. Jae Park (1)
  5. Lee Jones (1)
  6. Michael Morris (1)

More People

Years
  1. 2020 (7)
Publishers
  1. European Society for Medical Oncology (7)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 4-year follow-up of the phase III CheckMate 214 trial
    Journal Article

    Albiges, L.; Tannir, N. M.; Burotto, M.; McDermott, D.; Plimack, E. R.; Barthélémy, P.; Porta, C.; Powles, T.; Donskov, F.; George, S.; more...
    ESMO Open (2020)

    Fulltext@MSK | Save
  • Body weight and return to work among survivors of early-stage breast cancer
    Journal Article

    Di Meglio, A.; Menvielle, G.; Dumas, A.; Gbenou, A.; Pinto, S.; Bovagnet, T.; Martin, E.; Ferreira, A. R.; Vanlemmens, L.; Arsene, O.; more...
    ESMO Open (2020)

    Fulltext@MSK | Save
  • Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer
    Journal Article

    Rao, A.; Scher, H. I.; De Porre, P.; Yu, M. K.; Londhe, A.; Qi, K.; Morris, M. J.; Ryan, C.
    ESMO Open (2020)

    Fulltext@MSK | Save
  • ESMO presidential symposium wrap up: The ClarIDHy trial
    Miscellaneous

    Abou-Alfa, G. K.
    ESMO Open (2020)

    Fulltext@MSK | Save
  • Managing toxicities with asparaginase-based therapies in adult all: Summary of an ESMO Open-Cancer Horizons roundtable discussion
    Review

    Burke, P. W.; Hoelzer, D.; Park, J. H.; Schmiegelow, K.; Douer, D.
    ESMO Open (2020)

    Fulltext@MSK | Save
  • How I treat adverse effects of CAR-T cell therapy
    Review

    Yáñez, L.; Alarcón, A.; Sánchez-Escamilla, M.; Perales, M. A.
    ESMO Open (2020)

    Fulltext@MSK | Save
  • Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: A subgroup analysis of the phase 3 CELESTIAL trial
    Journal Article

    Kelley, R. K.; Ryoo, B. Y.; Merle, P.; Park, J. W.; Bolondi, L.; Chan, S. L.; Lim, H. Y.; Baron, A. D.; Parnis, F.; Knox, J.; more...
    ESMO Open (2020)

    Fulltext@MSK | Save

    • ESMO Open – authorized name for:

    Name ISSN / ISBN Publisher
    ESMO Open 2059-7029 BMJ Publishing Group Ltd.
    ESMO Open 20597029 The Authors
    ESMO Open 20597029 Unknown
    ESMO Open 20597029 The Pfizer, The Author(s)
    ESMO Open 2059-7029 Elsevier Inc.
    ESMO Open 2059-7029 BMJ Publishing Group Ltd.
    ESMO Open 2059-7029 BMJ Publishing Group Ltd.
    ESMO Open 2059-7029 BMJ Publishing Group Ltd.
    ESMO Open 2059-7029 BMJ Publishing Group Ltd.
    ESMO Open 2059-7029 BMJ Publishing Group Ltd.
    ESMO Open 2059-7029 BMJ Publishing Group Ltd.
    ESMO Open 20597029 The Author(s)
    ESMO Open 2059-7029 European Society for Medical Oncology
    ESMO Open 2059-7029 European Society for Medical Oncology
    ESMO Open 2059-7029 BMJ Publishing Group Ltd.
    ESMO Open 2059-7029 BMJ Publishing Group Ltd.
    ESMO open 2059-7029 BMJ Publishing Group Ltd.
    ESMO Open 20597029 European Society for Medical Oncology
    ESMO Open 20597029 Kura Oncology, Inc., The Author(s)
    ESMO Open 2059-7029 BMJ Publishing Group Ltd.
    ESMO Open 2059-7029 European Society for Medical Oncology
    ESMO Open 20597029 2022
    ESMO Open 2059-7029 BMJ Publishing Group Ltd.
    ESMO Open 2059-7029 BMJ Group
    ESMO Open 2059-7029 BMJ Group